Skip to main content
SRTA
NASDAQ Industrial Applications And Services

Strata Critical Medical Lifts 2026 Outlook After 61% Revenue Jump in Q2

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
8
Price
$5.72
Mkt Cap
$480.222M
52W Low
$3.675
52W High
$6.5
52W Position info
56% above low
Off High info
12% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

SRTA sits 56% above its 52-week low of $3.675.

Summary

Strata Critical Medical posted Q2 2026 revenue of $72.5M, up 60.7% YoY, and raised its full-year revenue and Adjusted EBITDA guidance. The quarter also saw three acquisitions close and a deal signed to take over Statline's organ placement relationships.


Key Events · Earnings and Guidance · SRTA

  • Q2 Revenue Surges 61%

    Total revenue reached $72.5 million, driven by 6.9% growth in Logistics and the addition of the Clinical segment, which contributed $24.3 million.

  • Full-Year Guidance Raised

    2026 revenue guidance increased to $285-295 million (from $260-275 million) and Adjusted EBITDA to $33-35 million (from $29-33 million), reflecting strong performance and acquisition contributions.

  • Adjusted EBITDA Hits $7.9M

    Adjusted EBITDA of $7.9 million (10.9% margin) was up from $2.5 million a year ago, driven by higher gross profit and operating leverage.

  • Three Bolt-On Acquisitions Closed

    Completed acquisitions of Louisville Perfusion Services, Heart and Lung Transplant National Recovery Program, and Ohio Valley Perfusion Associates, adding over $6 million in projected annualized Adjusted EBITDA.


Analysis · SRTA · Industrial Applications And Services

A 61% year-over-year revenue surge to $72.5 million—fueled by organic logistics growth and the new clinical business—powered Strata Critical Medical's strong second quarter. The company raised its full-year 2026 revenue and Adjusted EBITDA guidance, underscoring confidence in its acquisition-led expansion. Adjusted EBITDA of $7.9 million and positive free cash flow of $2.9 million highlight improving profitability, even as a GAAP net loss of $10.5 million reflects non-cash charges from earn-out revaluations and accelerated amortization. While the updated outlook and operational momentum point to continued growth, integration risks from the three bolt-on acquisitions completed during the quarter warrant attention.

At the time of this filing, SRTA was trading at $5.72 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $480.2M. The 52-week trading range was $3.68 to $6.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SRTA - Latest Insights

SRTA
Aug 04, 2026, 7:07 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $5.72
Real-time Price: $5.96 info
Change: +$0.240 (+4%) info
Market Cap: $480.222M info
SRTA
Jul 31, 2026, 9:26 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.14
Real-time Price: $5.96 info
Change: +$0.8232 (+16%) info
Market Cap: $480.222M info
SRTA
Jun 24, 2026, 9:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $5.61
Real-time Price: $5.96 info
Change: +$0.350 (+6%) info
Market Cap: $480.222M info
SRTA
Jun 02, 2026, 9:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $6.20
Real-time Price: $5.96 info
Change: -$0.2389 (-4%) info
Market Cap: $480.222M info
SRTA
May 06, 2026, 11:53 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.33
Real-time Price: $5.96 info
Change: +$0.635 (+12%) info
Market Cap: $480.222M info